Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.

Journal of cachexia, sarcopenia and muscle - 1 Dec 2018

González-Sánchez Jessica, Sánchez-Temprano Agustín, Cid-Díaz Tania, Pabst-Fernández Regina, Mosteiro Carlos S, Gallego Rosalía, Nogueiras Ruben, Casabiell Xesús, Butler-Browne Gillian S, Mouly Vincent, Relova José Luis, Pazos Yolanda, Camiña Jesús P

Abstract excerpt

BACKGROUND: This study was performed to test the therapeutic potential of obestatin, an autocrine anabolic factor regulating skeletal muscle repair, to ameliorate the Duchenne muscular dystrophy (DMD) phenotype. METHODS AND RESULTS: Using a multidisciplinary approach, we characterized the ageing-related preproghrelin/GPR39 expression patterns in tibialis anterior (TA) muscles of 4-, 8-, and 18-week-old mdx mice...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ghrelin
Share to Mice, Inbred mdx

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle Fibers, Skeletal

Share to Muscle Strength

Share to Muscular Dystrophy, Duchenne

Share to Proteolysis

Share to Receptors, G-Protein-Coupled

Share to Sarcolemma

Source

Open in PubMed Open full text

Identifiers

PMID: 30216693
DOI: 10.1002/jcsm.12338
PMCID: PMC6240759

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improvement of Duchenne muscular dystrophy phenotype following obestatin treatment.PMID 30216693Read ↗

The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targetsSemantic proximity Read ↗

Enhanced skeletal muscle fatigue tolerance through cell transplantation-mediated dystrophin supplementation in a mouse model of Duchenne Muscular DystrophySemantic proximity Read ↗

Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophySemantic proximity Read ↗

Tongue muscle is protected from dystrophic changes in the Duchenne Muscular Dystrophy RatSemantic proximity Read ↗

The adiponectin analogue ALY688-SR attenuates diaphragm fibrosis, atrophy and mitochondrial stress in a mouse model of Duchenne muscular dystrophySemantic proximity Read ↗

Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization.Semantic proximity Read ↗

Dynamic transcriptomic analysis reveals suppression of PGC1α/ERRα drives perturbed myogenesis in facioscapulohumeral muscular dystrophySemantic proximity Read ↗

miR‐29c improves skeletal muscle mass and function throughout myocyte proliferation and differentiation and by repressing atrophy‐related genesSemantic proximity Read ↗

Vitamin D binding protein induces skeletal muscle atrophy and contributes to cancer-associated muscle wastingSemantic proximity Read ↗

Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and NewSemantic proximity Read ↗

Muscular Dystrophies and Therapeutic Potential of Medicinal PlantsSemantic proximity Read ↗

Skeletal muscle fibre plasticity in response to selected environmental and physiological stimuli.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.